Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on December 11, 2018, at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2018.

Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results

Pasadena. CA | Posted on November 27th, 2018

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm . For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 6744427.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 6744427.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Machine learning speeds modeling of experiments aimed at capturing fusion energy on Earth May 17th, 2019

Manipulating atoms one at a time with an electron beam: New method could be useful for building quantum sensors and computers May 17th, 2019

New surface treatment could improve refrigeration efficiency: A slippery surface for liquids with very low surface tension promotes droplet formation, facilitating heat transfer May 17th, 2019

Generating high-quality single photons for quantum computing: New dual-cavity design emits more single photons that can carry quantum information at room temperature May 17th, 2019

Nanomedicine

Better microring sensors for optical applications May 10th, 2019

New efficient way to engineer nanostructures mimicking natural immune response complexes: Novel method to engineer large multi-antibody-like nanostructures using DNA nanotechnology; the results demonstrate the potential for assembly of multiple proteins and also other materials t May 10th, 2019

Nanotubes enable travel of Huntington's protein: Rhes protein makes its own road to convey disease drivers May 10th, 2019

A cautionary tale for researchers working on selective drug delivery May 9th, 2019

Announcements

Machine learning speeds modeling of experiments aimed at capturing fusion energy on Earth May 17th, 2019

Manipulating atoms one at a time with an electron beam: New method could be useful for building quantum sensors and computers May 17th, 2019

New surface treatment could improve refrigeration efficiency: A slippery surface for liquids with very low surface tension promotes droplet formation, facilitating heat transfer May 17th, 2019

Generating high-quality single photons for quantum computing: New dual-cavity design emits more single photons that can carry quantum information at room temperature May 17th, 2019

Financial Reports

180 Degree Capital Corp. Reports Net Asset Value per Share of $2.76 as of March 31, 2019; an Increase of 4.5% From December 31, 2018 May 1st, 2019

180 Degree Capital Corp. to Report First Quarter 2019 Financial Results on Wednesday, May 1, 2019 and to Host a Conference Call on Thursday, May 2, 2019 April 26th, 2019

Nanometrics to Announce First Quarter Financial Results on April 30, 2019 April 10th, 2019

Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results January 25th, 2019

Events/Classes

CEA-Leti Develops CMOS Process for High-Performance MicroLEDs That Could Overcome Display-Size Obstacles: New Concept Creates All-in-One RGB MicroLEDs, Eliminates Several Transfer Steps to Receiving Substrate & Boosts Performance May 16th, 2019

Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences May 3rd, 2019

Nanometrics Announces Participation in Upcoming Investor Conferences May 3rd, 2019

180 Degree Capital Corp. to Report First Quarter 2019 Financial Results on Wednesday, May 1, 2019 and to Host a Conference Call on Thursday, May 2, 2019 April 26th, 2019

Nanobiotechnology

New efficient way to engineer nanostructures mimicking natural immune response complexes: Novel method to engineer large multi-antibody-like nanostructures using DNA nanotechnology; the results demonstrate the potential for assembly of multiple proteins and also other materials t May 10th, 2019

Nanotubes enable travel of Huntington's protein: Rhes protein makes its own road to convey disease drivers May 10th, 2019

A cautionary tale for researchers working on selective drug delivery May 9th, 2019

Vaccine design can dramatically improve cancer immunotherapies: Effectiveness depends on molecular architecture and 3D presentation of components May 6th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project